Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2103341 | 0.87 | EGFR (0.82) | EGFRERBB2 | |
| SCHEMBL6668474 | 0.85 | HTT (0.68) | EGFRERBB2 | |
| SCHEMBL4586685 | 0.82 | EGFR (0.75) | EGFRERBB2 | |
| SCHEMBL27685863 | 0.81 | EGFR (0.73) | EGFRERBB2 | |
| SCHEMBL27923391 | 0.81 | EGFR (0.73) | EGFRERBB2 | |
| SCHEMBL29690398 | 0.81 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL30513 | 0.81 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL6663823 | 0.81 | ALK (0.74) | EGFRKIT | |
| SCHEMBL6664062 | 0.77 | EGFR (0.72) | EGFR | |
| SCHEMBL2987637 | 0.76 | EGFR (0.73) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004013091-A2 | 4-ANILIDO SUBSTITUTED QUINAZOLINES AND USE THEREOF AS INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-02-12 | — | — | WO | claimed |
| WO-2004013091-A2 | 4-ANILIDO SUBSTITUTED QUINAZOLINES AND USE THEREOF AS INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-02-12 | — | — | WO | disclosed |